News
Stoke Therapeutics and Biogen have begun dosing in the global Phase III EMPEROR study of zorevunersen for Dravet syndrome, ...
Cambridge, Massachusetts Wednesday, August 13, 2025, 15:00 Hrs [IST] ...
Stoke Therapeutics Inc (STOK) reports promising advancements in its Dravet syndrome program and strategic partnerships, ...
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $24.5, a high estimate of $30.00, and a low estimate of $22.00. This upward trend is apparent, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback